NCT06461962 Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement
| NCT ID | NCT06461962 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oregon Health and Science University |
| Condition | Methamphetamine Use |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-08-19 |
| Primary Completion | 2029-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-08-19 with a primary completion date of 2029-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of PEER-Heart is to implement and assess feasibility and preliminary effectiveness of a community peer-facilitated screening for methamphetamine-associated heart failure (MAHF) and linkage to evidence-based cardiology care for people who use methamphetamine in rural areas.
Eligibility Criteria
Inclusion Criteria: * Patient-defined regular use of methamphetamine in the last year * Any methamphetamine use in the past 30 days * Age 18 years or older * No client-reported diagnosis of heart failure * Able to communicate in English * Screen positive for potential methamphetamine-associated heart failure (MAHF) defined as B type natriuretic peptide (BNP) ≥50 pg/ml, or QRS width ≥120ms, or presence of any clinical heart failure symptoms Exclusion Criteria: * Self-reported engagement in medical care for heart failure in past 6 months. * Actively taking medications for heart failure.
Contact & Investigator
Brian Chan, MD, MPH
PRINCIPAL INVESTIGATOR
Oregon Health and Science University
Frequently Asked Questions
Who can join the NCT06461962 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Methamphetamine Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06461962 currently recruiting?
Yes, NCT06461962 is actively recruiting participants. Contact the research team at chanbri@ohsu.edu for enrollment information.
Where is the NCT06461962 trial being conducted?
This trial is being conducted at Portland, United States.
Who is sponsoring the NCT06461962 clinical trial?
NCT06461962 is sponsored by Oregon Health and Science University. The principal investigator is Brian Chan, MD, MPH at Oregon Health and Science University. The trial plans to enroll 200 participants.